Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data after PAK2 knockdown in head and neck cancer cells

ABSTRACT: Expression data after PAK2 knockdown in head and neck cancer cells

PROVIDER: PRJNA450818 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data after PAK2 knockdown in head and neck cancer cells

Project description:Epigenetic mechanisms play an important role in the cellular development and maintenance of cellular homeostasis. Any alteration of epigenetic mechanisms via the changes in DNA methylation and histone modification may lead to various diseases including cancer. The differential expression of histone modifiers has been observed in various malignancies. We used microarray to detail the differential gene-expression pattern of head and neck (HNC) cancer cells upon depletion of p21 activated kinase (PAK2). we identified distinct class of downregulated genes, majorly associated with cellular proliferation and tumorigenesis.

2018-08-07 | GSE113322 | GEO

Expression data from ALDH2 knockdown in head and neck cancer cells.

Project description:Expression data from ALDH2 knockdown in head and neck cancer cells.

| PRJNA1066363 | ENA

Global hypomethylation identifies loci targeted for hypermethylation in head and neck cancer: normal head and neck tissue

Project description:Genome-wide DNA methylation profiling of head and neck squamous cell carcinomas. The Illumina Infinium 27k Human DNA methylation BeadChip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in fresh-frozen tumor tissues. Samples included 91 tumors from the oralpharynx and larynx, reflecting all stages of disease, 18 normal head and neck National Disease Research Interchange (NDRI) samples, and 213 normal control blood samples. Bisulphite-converted DNA from the 18 normal head and neck samples were hybridized to the Illumina Infinium 27k Human Methylation Beadchip v1.2.

2011-10-27 | E-GEOD-25083 | biostudies-arrayexpress

Knockdown of DKK3 decreases malignant property in head and neck squamous cell carcinoma-derived HSC-3 cells.

Project description:We hypothesized that DKK3 may exert oncogenic function supecifically in head and neck squamous cell carcinoma (HNSCC). DKK3 knockdown in HNSCC cell resulted in decreased cellular proliferation, migration, invasion and in vivo tumor growth.

2018-11-30 | GSE107403 | GEO

Global hypomethylation identifies loci targeted for hypermethylation in head and neck cancer

Project description:This SuperSeries is composed of the following subset Series: GSE25083: Global hypomethylation identifies loci targeted for hypermethylation in head and neck cancer: normal head and neck tissue GSE25089: Global hypomethylation identifies loci targeted for hypermethylation in head and neck cancer: HNSCC GSE25091: Global hypomethylation identifies loci targeted for hypermethylation in head and neck cancer: blood controls Refer to individual Series

2011-10-27 | E-GEOD-25093 | biostudies-arrayexpress

Head and neck cancer neural reprogramming

Project description:Head and neck cancer neural reprogramming

| PRJNA589293 | ENA

STAT1 and Head and Neck Cancer

Project description:STAT1 and Head and Neck Cancer

| PRJNA816884 | ENA

Heterogeneity in head and neck cancer

Project description:Heterogeneity in head and neck cancer

| PRJNA713427 | ENA

Global hypomethylation identifies loci targeted for hypermethylation in head and neck cancer: normal head and neck tissue

2011-10-28 | GSE25083 | GEO

Gene expression data from head and neck cancer patient derived xenografts

Project description:Head and neck cancer is a hetergeneous disease. Based on previoulsy defined molecular subtypes we associated gene expression with response to different compounds. We used microarry gene expression for molecular subtyping Cetuximab is the single targeted therapy approved for the treatment of head and neck cancer (SCCHN). Predictive biomarkers have not been established in the clinical setting and patient stratification based on molecular tumor profiles has not been possible. Since EGFR pathway activation is pronounced in basal subtype, we hypothesized this activation could be a predictive signature for an EGFR directed treatment. From our patient derived xenograft platform of head and neck cancer, 28 models were subjected to Affymetrix gene expression studies on HG U133+ 2.0. Based on the expression of 821 genes, the subtype of each of the 28 models was determined by integrating gene expression profiles through centroid-clustering with previously published gene expression data by Keck et al.,CCR 2015. Response was evaluated by comparing tumor volume at treatment initiation and after three weeks of treatment (RTV).

2016-10-01 | GSE84713 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data